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STAT3, an essential transcription factor with pleio-
tropic functions, plays critical roles in the pathogen-
esis of autoimmunity. Despite recent data linking
STAT3 with inflammatory bowel disease, exactly
how it contributes to chronic intestinal inflammation
is not known. Using a T cell transfer model of colitis,
we found that STAT3 expression in T cells was essen-
tial for the induction of both colitis and systemic
inflammation. STAT3 was critical in modulating
the balance of T helper 17 (Th17) and regulatory T
(Treg) cells, as well as in promoting CD4+ T cell prolif-
eration. We used chromatin immunoprecipitation and
massive parallel sequencing (ChIP-Seq) to define the
genome-wide targets of STAT3 in CD4+ T cells. We
found that STAT3 bound to multiple genes involved
in Th17 cell differentiation, cell activation, prolifera-
tion, and survival, regulating both expression and
epigenetic modifications. Thus, STAT3 orchestrates
multiple critical aspects of T cell function in inflamma-
tion and homeostasis.
INTRODUCTION
Signal transducer and activator of transcription 3 (STAT3) is
a transcription factor that serves critical functions in develop-
ment, cell growth, and homeostasis in a variety of tissues (Hirano
et al., 2000; Levy and Lee, 2002). Germline deletion in mice leads
to embryonic lethality most likely due to STAT3’s essential func-
tions in mediating leukemia inhibitory factor (LIF) signaling as
well as other gp130 family cytokines (Takeda et al., 1997).
Conversely, inappropriate activation of STAT3 is associated
with malignant transformation and the pathogenesis of various
types of cancers (Haura et al., 2005). In hematopoietic cells,
STAT3 is an important negative regulator of the granulocyte
colony-stimulating factor (G-CSF) pathway and granulopoiesis
and is essential for the actions of interleukin-10 (IL-10) (Murray,
2006).Surprisingly, despite its critical roles in other tissues, condi-
tional deletion of STAT3 in T cells revealed no overt develop-
mental deficits (Takeda et al., 1998). Even though Stat3/
T cells were reported to have reduced IL-6-dependent prolifera-
tion in vitro, mice lacking Stat3 in their T cells had normal thymic
development and peripheral T cell compartments (Akaishi et al.,
1998). After activation, CD4+ T cells can differentiate into special-
ized subsets in the periphery, which are required for proper
immune regulation and host defense. In addition to previously
recognized T helper 1 (Th1) and Th2 fates, naive CD4+ T cells
can also differentiate into Th17 and regulatory T (Treg) cells; the
balance of Th17 and Treg cells is now considered to be critical
for host immunity and the preservation of tolerance (Bettelli
et al., 2008; Stockinger and Veldhoen, 2007; Weaver et al., 2007;
Yang et al., 2008a). Cytokines that activateSTAT3, including IL-6,
IL-21 and IL-23, are important drivers of Th17 cell differentiation
and promote immunity against extracellular bacteria and fungi
(Aggarwal et al., 2003; Bettelli et al., 2006; Nishihara et al., 2007;
Nurieva et al., 2007). Accordingly, we and others have shown that
STAT3plays a critical role in thedifferentiation ofCD4+T cells into
Th17 cells (Chen et al., 2006; Laurence et al., 2007; Mathur et al.,
2007; Wei et al., 2007; Yang et al., 2007). Patients with Job’s or
Hyper IgE Syndrome (HIES) have dominant-negative mutations
of STAT3 and are deficient in Th17 cells, underscoring the close
link betweenSTAT3 andTh17 cells (Holland et al., 2007;Maet al.,
2008; Milner et al., 2008; Minegishi et al., 2007).
The human inflammatory bowel diseases (IBDs) comprise
a wide spectrum of disorders, characterized by chronic inflam-
mation of the intestine, and several lines of evidence point to
the potential involvement of STAT3 and Th17 cells in disease
pathogenesis. Genome-wide association studies have identified
polymorphisms in the IL23R, JAK2, and STAT3 genes associ-
ated with increased susceptibility to IBDs (Barrett et al., 2008;
Duerr et al., 2006). Furthermore, phosphorylated STAT3 and
IL-17 are features of the inflammatory response in IBDs and
colitis models, but the requirement for STAT3 inmodels of colitis,
particularly with respect to T cell-dependent pathology, has not
been explored (Fujino et al., 2003; Suzuki et al., 2001). Moreover,
despite the link between STAT3 and models of Th17 cell-medi-
ated diseases, our understanding of how STAT3 contributes to
immunoregulation in terms of its gene targets is remarkably
limited (Harris et al., 2007; Liu et al., 2008).Immunity 32, 605–615, May 28, 2010 ª2010 Elsevier Inc. 605
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essential for driving both colitis and systemic inflammation not
only by modulating Th17 and Treg cell differentiation but also
by allowing T cell homeostatic expansion. To comprehensively
delineate STAT3 targets in T cells, we employed chromatin
immunoprecipitation followed by massive parallel sequencing
(ChIP-Seq). We found that STAT3 binds most of the genes
shown to promote Th17 cell fate determination, as well as
many genes involved in T cell survival and proliferation. Thus,
STAT3 has diverse, yet critical functions in the differentiation,
proliferation, and survival of T cells in the setting of chronic
inflammatory disease.
RESULTS
STAT3 Is Required for T Cell-Dependent Colitis
To dissect the involvement of STAT3 in chronic intestinal inflam-
mation, we used a T cell-transfer colitis model in which
lymphopenic Rag2/ mice were reconstituted with CD4+
CD45RBhiCD25 (RBhi) naive T cells from control (Stat3fl/fl) or
Stat3/ (Cd4 Cre; Stat3fl/fl) mice and monitored for develop-
ment of inflammatory disease. As expected, mice reconstituted
with control T cells began to lose weight at 5 weeks, whereas
mice that received Stat3/ T cells continued to gain weight
(Figure 1A). We confirmed clinical signs of colitis by evaluating
colonic inflammation histologically. Mice that received control
T cells developed marked inflammation in the colon at 9 weeks
(Figures 1B and 1C). In contrast, mice that received Stat3/
T cells had no colonic inflammation and were indistinguishable
from unreconstituted Rag2/ controls or Rag2/ mice that
received both control naive and Treg cells.
In addition to localized colonic pathology, transfer of naive
T cells into lymphopenic hosts induces systemic inflammation
manifested by splenic enlargement and elevated serum levels
of inflammatory cytokines and chemokines. Accordingly, we
found thatRag2/mice reconstituted with control T cells devel-
oped splenomegaly, associated with the presence of IL-6, IL-
12p70, MCP-1, and TNF-a in the serum (Figures 1D and 1E). In
contrast, mice reconstituted with Stat3/ T cells had normal-
sized spleens and significantly lower serum concentrations of
inflammatory cytokines, whereas concentrations of IL-10 were
similar to controls (Figure 1E). STAT3 was therefore critical for
driving not only the tissue-specific pathology in the colon but
also systemic inflammatory responses.
STAT3 Is Required for Th17Cell Differentiation in Colitis
STAT3 is necessary for Th17 cell differentiation in vitro and has
been implicated in Th17 cell-mediated pathology in othermodels
of autoimmunity. To test whether STAT3 is critical for Th17 cell
generation in T cell-transfer colitis, we harvested cells from the
colon lamina propria (LP), mesenteric lymph nodes (MLNs),
and spleens of Rag2/ mice at 9 weeks after reconstitution
with control or Stat3/ naive T cells and measured intracellular
IL-17A protein in CD4+ T cells by flow cytometry. Although IL-
17A-producing T cells were present in the colon LP, MLNs,
and spleen of Rag2/ mice that received control T cells, the
proportion and absolute number of IL-17A+ T cells was signifi-
cantly reduced in all tissues of Rag2/ mice reconstituted
with Stat3/ T cells (Figures 2A and 2B and Figure S1A available606 Immunity 32, 605–615, May 28, 2010 ª2010 Elsevier Inc.online). Interferon-gamma (IFN-g) is another cytokine commonly
induced during colitis and implicated in IBD pathogenesis
(O’Connor et al., 2009; Powrie et al., 1994). We did not observe
a reduction in the proportion of IFN-g-producing CD4+ T cells
in any of the tissues of mice reconstituted with Stat3/ naive
T cells compared to controls (Figure 2C). On the contrary, a
significantly higher proportion of IFN-g+ CD4+ T cells were
present in the spleens of mice that received Stat3/ T cells;
however, the absolute number of IFN-g+ T cells in the tissueswas
not significantly different between the two groups (Figure S1B).
Thus, our data support the conclusion that STAT3 is necessary
for IL-17A but not IFN-g production by CD4+ T cells in this model
of colitis.
STAT3 Inhibits Regulatory T Cell Conversion
Treg cells are a specialized population of CD4+ T cells that
express the forkhead/winged-helix protein Foxp3, and they
dampen inflammatory responses and prevent autoimmunity
(Josefowicz and Rudensky, 2009). In addition to eliciting inflam-
mation, both IL-23 and IL-6 inhibit Treg cell differentiation and
can thereby contribute to immune pathology (Izcue et al.,
2008; Korn et al., 2008). Because IL-6-mediated inhibition of
Foxp3 expression in vitro is STAT3-dependent (Yao et al.,
2007), we assessed the impact of STAT3 on Treg cell homeo-
stasis in the intestine in vivo, both at the steady state and in
the context of inflammatory disease. We first examined the
frequency of Foxp3+ T cells in unperturbed Cd4 Cre; Stat3fl/fl
mice and littermate control Stat3fl/fl mice but found that both
had equivalent proportions and absolute numbers of Foxp3+
T cells in their tissues (Figures 3A and 3B). These findings argue
that STAT3 has little effect on Foxp3 expression in the absence
of inflammation.
To investigate the importance of STAT3 in Treg cell differenti-
ation in the setting of inflammation, we examined the conversion
of Stat3/ naive T cells into Foxp3+ Treg cells in the colitis
model. In Rag2/ mice reconstituted with control naive
T cells, a small proportion of CD4+ T cells expressed Foxp3 in
all of the tissues examined (Figures 3C and 3D). Conversely,
we found a significantly greater proportion of Foxp3+ T cells in
colons and spleens of Rag2/ mice that received Stat3/
T cells. The absolute numbers of Foxp3+ T cells were not
different; however, we attribute this to poor expansion of
Stat3/ T cells (discussed below, Figure S2A). Similar propor-
tions of IL-10+ T cells were also present in both groups of mice
(Figure S2B). Thus, STAT3 appeared to inhibit the conversion
of naive T cells into Foxp3+ cells in vivo in the inflammatory
setting. In addition to the paucity of IL-17-producing cells, these
data provide another explanation for why mice reconstituted
with Stat3/ T cells did not develop colitis or systemic disease.
STAT3 Directly Regulates Most Genes Involved in Th17
Cell Differentiation
Our data point to nonredundant, essential roles for STAT3 in
regulating the balance between Th17 and Treg cell differentiation
in vivo. To better define how STAT3 contributes to this decision,
we identified STAT3 targets genome-wide using transcriptional
profiling and chromatin immunoprecipitation coupled with
massive parallel sequencing (ChIP-Seq). We found that STAT3
bound to more than 3000 genes and among its targets, we
Figure 1. Intrinsic Requirement for STAT3 in
T Cell-Dependent Colitis
(A–E) CD4+CD45RBhiCD25 naive T cells from
control (Stat3fl/fl) or Stat3/ (Cd4 Cre; Stat3fl/fl)
mice were transferred into Rag2/ mice, which
were monitored for evidence of colitis.
(A) Weight loss (percentage of initial weight at day
0) was calculated for each mouse over 9 weeks.
Data show mean (±SEM) weight changes for
each group (n = 4–5 mice) and are representative
of four independent experiments.
(B and C) Colitis was assessed histologically at 9
weeks and severity was scored by markers of
inflammation (Izcue et al., 2008). Each point repre-
sents an individual mouse and the data are pooled
from three independent experiments. Unreconsti-
tuted Rag2/ mice and mice that received naive
T cells with CD4+CD25+ Treg cells were included
as controls.
(D and E) Systemic inflammation was assessed by
measuring (D) spleen weights and (E) mean
(±SEM) concentrations of inflammatory cytokines
and chemokines in the serum. Data are represen-
tative of two independent experiments. *p < 0.05,
**p < 0.005, ***p < 0.0005.
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(Table S1).
As previously reported, we found that STAT3 bound to the
Il17a and Il21 promoters (Figure 4A) (Chen et al., 2006; Nurieva
et al., 2007; Wei et al., 2007). Additionally, STAT3 bound to the
Il17f promoter and the intergenic region of the Il17a and Il17f
locus. In fact, intergenic STAT3 binding sites resided within
conserved noncoding sequences (CNSs) and contained STAT
consensus motifs (Figure 4A and Figure S3A). We also found
STAT3 bound at multiple sites in the Il6ra gene (Figure 4A) and
at sites in the Il23r and the Ccr6 genes (Table S1).
Gene expression is regulated by transcription factor binding
and epigenetic modifications that control accessibility of the
chromatin to transcriptional machinery (Kouzarides, 2007).
Epigenetic changes also affect cell lineage commitment and
phenotypic stability by controlling transcription of essential
genes (Goldberg et al., 2007). To assess the role of STAT3 in
regulating epigenetic modifications, we cultured WT andImmunity 32, 605–6Stat3/ naive T cells for 3 days under
Th17 cell-polarizing conditions
(Figure S3B) and measured histone 3
lysine 4 trimethylation (H3K4me3),
a mark found at active gene loci, by
ChIP-Seq (Figure 4A and Table S1). We
found that in WT T cells, STAT3-bound
genes Il17a, Il17f, Il21, and Il6ra all con-
tained H3K4me3 marks; however, these
marks were absent or reduced in
Stat3/ T cells. Therefore, STAT3 regu-
lates positive epigenetic modifications
of its target genes, and likely contributes
to stability of the Th17 phenotype.
To assess whether STAT3 binding and
H3K4me3 correlated with modulation ofgene expression, we performed transcriptional profiling using
microarray and quantitative PCR. Expression of IL17a, IL21,
and Il6ra was markedly impaired in Stat3/ T cells compared
to controls, particularly when the cells were differentiated with
IL-6 and TGF-b (Figure 4B). We also found that expression of
IL17f (not present on Affymetrix chips) was decreased in
Stat3/ T cells compared to control T cells (Figure 4C). In
contrast, expression of Ccr6 was not changed (Figure 4B).
Thus, both STAT3 binding and increased H3K4me3 to genes
were associated with STAT3-dependent expression.
Th17 cell differentiation is associated with expression of
several transcription factors, including RORgt, RORa, RUNX1,
BATF, IRF-4, AHR, and c-Maf (Bauquet et al., 2009; Bru¨stle
et al., 2007; Ivanov et al., 2006; Schraml et al., 2009; Veldhoen
et al., 2008; Yang et al., 2008b; Zhang et al., 2008). We assessed
STAT3 binding to these transcription factor genes to determine
whether it directly contributes to their regulation. RORgt, en-
coded byRorc, is themaster regulator of Th17 cell differentiation15, May 28, 2010 ª2010 Elsevier Inc. 607
Figure 2. Loss of STAT3Abrogates Th17 but
not Th1 Cell Responses
(A–C) Rag2/ mice were injected with naive
T cells from control (Stat3fl/fl) or Stat3/ (Cd4
Cre; Stat3fl/fl) mice.
(A) IL-17A production by CD4+ T cells in the colon
LP, MLNs, and spleen was measured.
(B) The overall proportion of IL-17A+ T cells repre-
sents data pooled from two independent experi-
ments.
(C) The proportions of IFN-g+ CD4+ T cells in the
tissues of Rag2/ mice were enumerated and
pooled from two independent experiments. See
also Figure S1. *p < 0.05, ***p < 0.0001.
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STAT3 also bound the related retinoid receptor gene, Rora, as
well as the Batf, Irf4, Ahr, and Maf genes (Figure 4A). We also
found that STAT3 regulated permissive H3K4me3 marks on
Rorc, Rora, and Batf but not on Irf4, Ahr, orMaf. This correlated
well with the magnitude of their differential expression deter-
mined by microarray (Figure 4B). Overall, these findings support
a direct function for STAT3 in regulating not only gene expres-
sion but also epigenetic modifications of key Th17 cell-related
genes.
Lymphopenia-Induced Expansion of CD4+ T Cells
Requires STAT3
An important hallmark of disease in the colitis model is the accu-
mulation of activated CD4+ T cells (Powrie et al., 1994). As ex-
pected, transfer of control (Stat3fl/fl) naive T cells into Rag2/
mice resulted in the accumulation of CD4+ T cells in the colon
LP, MLNs, and spleen after 9 weeks (Figure 5A). However, there
were significantly fewer Stat3/ CD4+ T cells in tissues of
Rag2/ recipient mice. Although this correlated well with
a lack of inflammation (Figure 1), we were interested in deter-
mining why Stat3/ T cells failed to accumulate in the lympho-
cyte-deficient environment.
Because Stat3/ T cells did not elicit inflammation in the
Rag2/ mice, we could not exclude that the lack of inflamma-
tory cytokines in the system contributed to their poor accumula-
tion within the tissues. To address this possibility, we induced
inflammation in Rag2/mice by concurrently transferring equal
numbers of wild-type (CD45.1) and Stat3/ naive T cells (Fig-
ures S4A and S4B). Substantial numbers of wild-type T cells608 Immunity 32, 605–615, May 28, 2010 ª2010 Elsevier Inc.accumulated in tissues of reconstituted
mice, but significantly fewer Stat3/
CD4+ T cells were present (Figure 5B).
This indicates that STAT3 has an impor-
tant, cell-intrinsic role in driving T cell
expansion in the context of inflammation
and its importance is particularly evident
in a competitive setting.
In a chronically lymphopenic Rag2/
mouse, commensal bacteria and self-
antigens along with cytokines drive the
initial rapid expansion of naive T cells
(Surh and Sprent, 2008). Therefore, theinability of Stat3/ T cells to accumulate could indicate a role
for STAT3 in early expansion, prior to the onset of inflammatory
disease. To test this, we transferred wild-type (CD45.1) or
Stat3/ naive T cells into Rag2/ mice. At 2 weeks, we found
significantly fewer Stat3/ CD4+ T cells in the spleen and lymph
nodes of the Rag2/ recipients than wild-type T cells (Fig-
ure 5C). Importantly, neither group of recipients had signs of
inflammation, supporting an essential function for STAT3 in early
lymphopenia-induced T cell expansion.
Proliferation of T cells also occurs as part of normal lymphoid
tissue development and in this context does not elicit inflamma-
tion. To examine the importance of STAT3 in homeostatic CD4+
T cell expansion in the setting of stem cell transplantation, we re-
constituted irradiatedRag2/micewith bonemarrow (BM) from
wild-type (CD45.1) or Cd4 Cre; Stat3fl/fl mice and examined
lymphoid compartments after 8 weeks. Although there were
comparable proportions of CD4+ T cells in the thymus, there
were significantly fewer CD4+ T cells in the spleens and lymph
nodes of mice reconstituted with BM from Cd4 Cre; Stat3fl/fl
mice (Figures 5D and 5E). We next used a model of competitive
bone marrow reconstitution to examine the ability of Stat3/
T cells to accumulate in the presence of normal T cells. Specifi-
cally, we irradiated Rag2/ mice and cotransferred bone
marrow cells from wild-type (CD45.1) and Cd4 Cre; Stat3fl/fl
mice at a 1:1 ratio (Figure 5F).We found that the absolute number
of Stat3/ CD4+ T cells was significantly less than wild-type
T cells in the peripheral lymphoid organs and in the thymus.
These findings support an essential function for STAT3 in regu-
lating CD4+ T cell proliferation not only in pathologic settings
but also during their development from precursor cells; in the
Figure 3. STAT3 Inhibits Regulatory T Cell
Conversion in Colitis
(A) The proportions and (B) absolute numbers
(mean ± SEM) of Foxp3-expressing CD4+ T cells
in the tissues of control (Stat3fl/fl) or Stat3/
(Cd4 Cre; Stat3fl/fl) mice are shown. Data are
representative of three independent experiments.
(C and D) Colitis was induced in Rag2/ mice as
described in Figure 1. Intracellular Foxp3 expres-
sion in the tissues is shown in (C), and in (D),
proportions of Foxp3+ cells among CD4+ T cells
represent data pooled from four independent
experiments. See also Figure S2. *p < 0.05,
**p < 0.01.
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competitive disadvantage.
STAT3 Plays a Nonredundant Role in CD4+ T Cell
Survival and Proliferation
The inability of Stat3/T cells to accumulate under both lym-
phopenic and homeostatic conditions could be due to defects
in proliferation, increased apoptosis, or both. To address these
possibilities, we first assessed the ability of carboxyfluorescein
succinimidyl ester (CFSE)-labeled naive T cells to proliferate
after transfer into Rag2/ mice. We examined the CD4+
T cells in the spleen and found that the majority of control
(Stat3fl/fl) T cells (86.4%) underwent multiple cell divisions after
5 days (Figure 6A). In contrast, fewer than half (39.2%) of
Stat3/ T cells had divided, as indicated by CFSE dilution. By
7 days, essentially all of the control T cells had divided
(98.11%), whereas 18% of Stat3/ T cells remained quiescent.
However, by 14 days, both the Stat3/ and control T cells had
undergone multiple rounds of division; similar levels of T cell
proliferation occurred in the MLNs (Figure S5A). Thus, we can
conclude that STAT3 influences the rate of CD4+ T cell prolifera-
tion and loss of Stat3 delays but does not abrogate T cell prolif-
eration. As a result, fewer Stat3/ T cells accumulate in tissues,
especially at early time points (Figure 6B and Figure S5B).
Apoptotic cells are rapidly cleared in vivo, making it difficult to
quantify cell death of adoptively transferred cells. Therefore, we
further assessed cell viability in vitro by culturing naive T cells
with anti-CD3 and anti-CD28 with or without STAT3-activating
cytokines, IL-6 and IL-21, measuring incorporation of propidium
iodide (PI) and surface expression of Annexin-V. In the absenceImmunity 32, 605–of exogenous cytokines (medium), the
proportion of apoptotic control and
Stat3/ T cells was roughly equivalent
(Figure 6C and Figure S5C). Addition of
IL-6 or IL-21 to cultures of control T cells
significantly reduced the proportion of
apoptotic cells. In contrast, Stat3/
T cells were not responsive to IL-6 or IL-
21 and had poor viability in all conditions.
Activation of T cells with anti-CD3 and
anti-CD28 results in endogenous IL-2
production. Consequently, addition of
excess exogenous IL-2, which preferen-tially activates STAT5, did not enhance the viability of either
the Stat3/ or control T cells. Taken together, these findings
support the contention that STAT3 regulates T cell survival and
proliferation, which in turn affect their ability to expand and elicit
inflammation in a lymphopenic host.
Direct Involvement of STAT3 in Regulating Cell Survival
and Proliferation Genes in CD4+ T Cells
STAT3 has been previously implicated in the regulation of genes
involved in cell survival and proliferation (Bourillot et al., 2009;
Hirano et al., 2000). However, there is a paucity of data showing
that STAT3 directly regulates expression of cell survival and anti-
apoptotic genes in CD4+ T cells. From our ChIP-Seq analysis, we
found direct STAT3 binding to multiple survival genes, including
Bcl2, Ier3, Fos, Jun, and Fosl2 (Figure 7A). Additionally, tran-
scriptional profiling revealed that these genes were inducible in
T cells by IL-6, but their induction was abrogated in Stat3/
T cells (Figures 7B and 7C). We also noted that H3K4me3,
permissive marks of active transcription, were present on all
genesbutwere not absent inStat3/Tcells. These findings indi-
cate that although expression of these genes is decreased in a
STAT3-dependent manner, they remain poised for transcription.
This fits with our conclusion that STAT3 is important but not the
only factor involved in regulating transcription of survival genes.
Taken together, the present data establish that STAT3 directly
regulates genes that control survival and proliferation of CD4+
T cells. This important function of STAT3 is manifested most
dramatically when T cells undergo expansion both in pathologic
settings like the colitis model and in noninflammatory lympho-
penic environments. However, in contrast to its roles in Th17615, May 28, 2010 ª2010 Elsevier Inc. 609
Figure 4. STAT3 Is Directly Involved in
Multiple Aspects of Th17 Cell Differentiation
(A) ChIP-Seq was performed on Th17 cells with
antibodies against phospho-STAT3 (second
panel) and histone 3 lysine 4 trimethylation
(H3K4me3) (lower panels). The locations of
conserved noncoding sequences (CNSs) are
shown in the top panel. The arrows indicate tran-
scription directionality. Scales are constant for all
genes and islands. See also Figure S3 and Table
S1.
(B and C) The effect of STAT3 on gene expression
in control or Stat3/ Th17 cells was determined
by (B) microarray analysis and (C) quantitative
PCR.
Immunity
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survival and proliferation; other factors can evidently contribute
to these processes.
DISCUSSION
STAT3 has now been genetically and functionally linked to the
pathogenesis of human IBD as well as other autoimmune
diseases, but our understanding of STAT3’s function in T cells
has been surprisingly limited. Here, we have shown that Stat3
expression by T cells is essential for their colitogenic activity in
a well-described model of colitis and systemic inflammation.
STAT3 contributes to T cell-mediated colitis in a number of
ways. First, it is essential for the differentiation of Th17 cells
in vivo; in its absence T cells are nonpathogenic and tend to
divert toward a Treg cell fate. Second, STAT3 mediates signals
that are crucial for CD4+ T cell proliferation and survival in vivo.
Using ChIP-Seq and transcriptional profiling, we identified610 Immunity 32, 605–615, May 28, 2010 ª2010 Elsevier Inc.multiple genes that are direct targets of
STAT3 in T cells. These included nearly
all of the genes known to regulate Th17
cell differentiation as well as genes that
promote survival and proliferation. Thus,
STAT3 has diverse and nonredundant
functions in T cells, both in pathogenic
and homeostatic settings.
The critical function for STAT3 in Th17
cell differentiation has been studied both
in vitro and in animal models of autoim-
munity. Here, we provide direct evidence
that STAT3 regulates the expression of
multiple genes essential for Th17 cell
development. We previously showed
that STAT3 binds to the Il17a promoter,
but the present data show that STAT3
also binds the Il17f promoter and the
intergenic region of these genes (Akimz-
hanov et al., 2007). In the future it will
be important to further examine how
STAT3 binding to intergenic sites contrib-
utes to its regulation of Il17a and Il17f
gene transcription. We also provide
evidence that STAT3 controls chromatin
accessibility at the Il17a, Il17f, and Il21genes by regulating histone modifications. This adds ano-
ther layer of complexity to STAT3’s role as a transcriptional
regulator.
Equally importantly, we have shown that STAT3 binds to and
regulates the expression of several major transcription factor
genes that drive Th17 cell differentiation. These include the
genes encoding RORgt, RORa, BATF, IRF4, AHR, and c-Maf:
factors important for promoting the program that leads to selec-
tive IL-17 production. Therefore, our findings support a broad
role for STAT3 as a critical regulator of the Th17 cell transcrip-
tional program. It will be useful to compare and contrast the array
of targets for each of these transcription factors, including
STAT3, to better define the hierarchy of interactions.
Previous in vitro studies have suggested that STAT3 inhibits
Treg cell differentiation. In the present study, we found that
STAT3 did not affect Treg cells in unperturbedmice. By contrast,
STAT3 did inhibit naive T cell conversion into Foxp3-expressing
cells in the context of inflammation, which is consistent with
Figure 5. STAT3 Is Required in Lymphopenia-Induced Expansion of CD4+ T Cells
(A) Rag2/mice were reconstituted with naive (RBhi) T cells from control (Stat3fl/fl) or Stat3/ (Cd4 Cre; Stat3fl/fl) mice. The absolute numbers of CD4+ T cells in
the tissues were quantified. Data are pooled from two independent experiments.
(B) The absolute numbers of CD4+ T cells in the tissues of Rag2/mice cotransferred with a 1:1 ratio of wild-type (CD45.1) and Stat3/ naive T cells. See also
Figure S4.
(C) The absolute numbers of CD4+ T cells in the spleen and LN ofRag2/mice 2 weeks after reconstitution with wild-type (CD45.1) or Stat3/ T cells are shown.
Data are representative of two independent experiments.
(D and E) Bone marrow (BM) cells from wild-type (CD45.1) or Stat3/ mice were transferred into irradiated Rag2/ mice. The proportions of CD4+ and CD8+
T cells in the thymus and spleen are shown in (D), and as shown in (E), absolute numbers (mean ± SEM) of CD4+ cells in the spleen and LN were determined.
(F) BM cells from wild-type (CD45.1) and Stat3/mice were cotransferred into irradiated Rag2/mice in a 1:1 ratio and the absolute numbers of CD4+ T cells in
the tissues were calculated. *p < 0.05, **p < 0.01, ***p < 0.0005.
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Defining Critical Roles of STAT3 in CD4+ T Cellsprevious work showing that both IL-6 and IL-23 inhibit regulatory
T cell differentiation in autoimmune disease (Izcue et al., 2008;
Korn et al., 2008). However, it remains uncertain how this nega-
tive regulation occurs. STAT3 could regulate Foxp3 indirectly by
enhancing RORgt expression, the latter being a factor that binds
to and suppresses Foxp3 function. Nonetheless, Foxp3 levels
are reduced in vitro by exposure to IL-6, supporting a specific
inhibitory role for STAT3 in Treg cells. Themechanism underlying
this effect is unclear. We also found proportionally more IFN-g+
T cells in the absence of STAT3, but again, STAT3 did not bind
the Ifng gene. However, these findings might be explained by
reduced IL-17 production, which has recently been reported to
inhibit IFN-g production in the setting of colitis (O’Connor
et al., 2009).In addition to effects on T cell differentiation, we also found
that STAT3 controls T cell proliferation and survival. We were
surprised by the extent to which STAT3 regulates this aspect
of T cell function given that the original description of mice lack-
ing Stat3 in T cells reported no effects on thymic or peripheral
T cell development. We found that Stat3/ T cells exhibited
reduced proliferation and failed to accumulate in the spleen or
colon after transfer to Rag2/ mice. Strikingly, even the pres-
ence of wild-type T cells and development of severe colitis did
not allowStat3/Tcells to expand. These results reveal a nonre-
dundant and cell-intrinsic requirement for STAT3 in T cell expan-
sion during an inflammatory response. Previous reports have
suggested that IL-6 is important for T cell survival in the context
of inflammation (Atreya et al., 2000). Additionally, IL-23 isImmunity 32, 605–615, May 28, 2010 ª2010 Elsevier Inc. 611
Figure 6. STAT3 Has a Nonredundant Role
in T Cell Survival and Proliferation
(A and B) Control (Stat3fl/fl) or Stat3/ (Cd4 Cre;
Stat3fl/fl) naive T cells were transferred into
Rag2/ mice and cell division was assessed by
CFSE dilution.
(B) The absolute numbers of CD4+ TCR-b+ cells in
the spleen at day 5 and 7 are shown; data are
representative of two independent experiments.
(C) Control and Stat3/ CD4+ T cells were
cultured for 3 days in medium or with the indicated
cytokines and the proportion of apoptotic
(Annexin-V/PI positive) cells was determined by
flow cytometry. Means (±SEM) of apoptotic cells
from three independent experiments are shown.
See also Figure S5. *p < 0.05; **p < 0.005.
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Defining Critical Roles of STAT3 in CD4+ T Cellssuggested to promote expansion of Th17 cells in peripheral
tissues, and specifically in the colon (data not shown)
(McGeachy et al., 2009). Therefore, at least in pathologic
settings, IL-6 and IL-23 are likely candidates for driving STAT3-
dependent expansion of CD4+ T cells.
The requirement for STAT3 in CD4+ T cell expansion was also
clearly evident in the absence of any overt inflammatory
response and particularly in the setting of competitive bone
marrow reconstitution. This is unexpected because IL-7 and
IL-15, which predominantly activate STAT5, have been
proposed to be the principal drivers of lymphopenia-induced
proliferation (Surh and Sprent, 2008). Thus, the STAT3-activating
cytokine responsible for this aspect of T cell homeostasis
remains to be identified.
Regardless of the cytokines responsible, it is clear from our
data that STAT3 directly regulates many antiapoptotic and pro-
proliferative genes in T cells. It has been previously suggested
that Bcl-2 is activated by STAT3, but we provide the first
evidence that STAT3 directly regulates Bcl2 expression. Fos
and Jun dimerize to form the activator protein 1 (AP-1) transcrip-
tion factor complex, which plays an important role in T cell acti-
vation. Interestingly, previous work has indicated that STAT3
cooperates with both Jun and Fos to enhance transcription of
IL-6-responsive genes (Schuringa et al., 2001). It is intriguing
therefore that STAT3 can directly regulate expression of Jun
and Fos and so potentially function in a positive feedback loop
to regulate gene expression. It will be important to examine these
pathways in more detail to gain insights into how they work
together to promote T cell expansion. Equally, the finding that612 Immunity 32, 605–615, May 28, 2010 ª2010 Elsevier Inc.proliferation is not abrogated in the
absence of STAT3 and that epigenetic
modifications of prosurvival genes are
regulated independently of STAT3 argues
that this factor acts in concert with other
transcription factors to regulate prolifera-
tion and cell survival.
In conclusion, our data highlight many
functions of STAT3 in CD4+ T cells not
previously appreciated and emphasize
the pleiotropic nature of this transcription
factor. In addition to multiple roles in
regulating Th17cell differentiation, STAT3contributes to T cell homeostasis, particularly in the context of
inflammation. Coupled with STAT3’s known immunosuppres-
sive function in innate and epithelial cells, our findings support
a complex role for STAT3 in the immune system (Pickert et al.,
2009; Takeda et al., 1999). Given the recent genetic data impli-
cating STAT3 in a number of human autoimmune diseases, it is
clear that more careful dissection of the many functions of this
key gene is warranted.
EXPERIMENTAL PROCEDURES
Mice
Cd4 Cre; Stat3fl/fl mice were generated as previously described (Lee et al.,
2002; Wei et al., 2007). B6.129 Rag2/ mice and B6.SJL-CD45.1 mice
were from Taconic Farms. All mice were handled and housed in specific path-
ogen-free facilities in accordance with the guidelines of the NIH Animal Care
and Use Committee.
Adoptive Transfer Model of Colitis
CD4+ T cells were enriched from the spleen and lymph nodes of control
(Stat3fl/fl) and Stat3/ (Cd4 Cre; Stat3fl/fl) mice with an AutoMACS cell sepa-
rator (Miltenyi Biotec), stained with PerCP Cy5.5 anti-CD4, FITC anti-CD25,
and PE anti-CD45RB (all obtained from BD Biosciences), and naive CD4+
CD25- CD45RBhi T cells were purified (>99%) by cell sorting (Moflo,Dako Cy-
tomation or FACSAria, BD Biosciences). CD4+CD45RBhiCD25 naive T cells
(4 3 105) were injected intravenously (i.v.) into age- and sex-matched
Rag2/ mice and intestinal inflammation was monitored. Control mice were
coinjected with 4 3 105 naive T cells and 1 3 105 CD4+CD45RBloCD25+
Treg cells or left unreconstituted. Mice were sacrificed at 8–10 weeks when
significant weight loss occurred in the control groups. Sections of the prox-
imal, mid-, and distal colon were fixed in buffered 10% formalin and stained
with hematoxylin and eosin (H&E) (Histoserv). Inflammation was assessed
Figure 7. STAT3 Directly Regulates Genes
Involved in CD4+ T Cell Survival and Prolifer-
ation
(A) STAT3 binding (second panel) and H3K4me3
modifications (lower panels) were determined by
ChIP-Seq. Conserved noncoding sequences are
shown in the top panel. Arrows indicate direction-
ality of transcription. See also Table S1.
(B and C) Control or Stat3/ T cells were cultured
for 3 days with the indicated cytokines and the
effect of STAT3 on gene expression was assessed
by (B)microarray and (C) quantitative PCR (mean ±
SEM; n = 2 samples).
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2006). Serum was collected and protein concentrations of IL-6, IL-12p70,
MCP-1, TNF-a and IL-10 were measured by cytometric bead assay (BD
Biosciences).
Isolation of Leukocyte Subpopulations and Flow Cytometry
Cell suspensions were prepared from the thymus, spleen, mesenteric lymph
nodes (MLNs), and colon lamina propria (LP) by methods previously described
(Uhlig et al., 2006). PerCP Cy5.5- or FITC- conjugated anti-CD4, PE-conju-
gated anti-TCR-b, FITC-conjugated anti-CD45.1, and APC-conjugated anti-
CD8 were from BD Biosciences. PE or FITC anti-Foxp3 staining set was
from eBioscience. For intracellular cytokine staining, cells were cultured for
4 hr with PMA (50 ng/ml), ionomycin (1 mg/ml) and BFA (GolgiPlug; BD Biosci-
ences), stained for CD4, fixed, and permeabilized in buffers from BD Biosci-
ences. Cells were stained with PE or APC anti-IFN-g, PE anti-IL-17A (all
from BD Biosciences) or Alexa Fluor-647 anti-IL-17A (eBioscience), or appro-
priate isotype controls (BD Biosciences).
For in vitro activation, naive T cells were cultured for 3 days with 5 mg/ml
each of platebound anti-CD3 and anti-CD28 (BD Biosciences) alone or withImmunity 32, 605–100 U/ml IL-2 (Peprotech), 10 ng/ml IL-6 (eBio-
science) and 10 ng/ml IL-21(R&D). FITC or APC
anti-Annexin-V antibody and propidium iodide
(BD Biosciences) were used for apoptosis assess-
ment. Cells were acquired on the FACSCaliber (BD
Biosciences) and analyzed with FlowJo 8.7.3 soft-
ware (Tree Star).
Homeostatic Proliferation and Stem Cell
Transplantation
For assessing early in vivo T cell expansion,
Rag2/mice were injected i.v. with 13 106 naive
T cells from WT (CD45.1), Stat3fl/fl, or Cd4 Cre;
Stat3fl/fl mice. Spleen and lymph nodes were har-
vested at 2 weeks and CD4+ T cell populations
were assessed by flow cytometry with CD4,
CD45.1, and TCR-b antibodies. Alternatively,
naive CD4+ T cells (1x 106) were purified by cell
sorting, labeled with carboxyfluorescein succini-
midyl ester (CFSE, 1 mM, Molecular Probes) and
injected i.v. into Rag2/ mice. After 5, 7, 9 or 14
days, spleen and MLN cells were harvested,
labeled with CD4 and TCR-b antibodies and
CFSE dilution was quantified by flow cytometry.
In competitive studies, Rag2/ mice were in-
jected i.v. with 4 3 105 naive T cells from Cd4
Cre; Stat3fl/fl and WT (CD45.1) mice, mixed at
a 1:1 ratio. At 10 weeks, CD4+ T cell populations
were assessed by flow cytometry as above.
For stem cell transplantation, bone marrow was
isolated from Cd4 Cre; Stat3fl/fl and WT (CD45.1)
mice and 3 3 106 cells were injected i.v. intogamma-irradiated Rag2/mice (900 rads). For the competitive reconstitution
experiments, Cd4 Cre; Stat3fl/fl and WT (CD45.1) bone marrow cells were
mixed at a 1:1 ratio (3 3 106 cells total) and injected i.v. into irradiated
Rag2/mice. Eight weeks later, spleen, thymus, and lymph nodes were har-
vested and T cell populations were assessed by flow cytometry with CD4,
CD8, and CD45.1 antibodies.
ChIP-Seq and Transcriptional Profiling
Control (Stat3fl/fl) and Stat3/ (Cd4 Cre; Stat3fl/fl) naive CD4+CD44CD62L+
T cells were isolated and sorted on the FACSAria flow cytometer. Cells
were cultured for 72 hr with CD3 (5 mg/ml) and CD28 (5 mg/ml), IL-6 (10 ng/ml),
and TGF-b (2.5 ng/ml) with blocking antibodies to 10 mg/ml IL-2, 10 mg/ml
IL-4, and 10 mg/ml IFN-g. Cells were restimulated for 1 hr with IL-6 (10 ng/ml)
and then processed for ChIP-Seq as previously described (Wei et al., 2009).
Antibodies against histone H3K4me3 (ab8580, Abcam) and phosphoserine
(PS)-STAT3 (Cat. #9134, Cell Signaling) were used. The ChIP DNA fragments
were blunt-ended, ligated to the illumina adaptors, and sequenced with the Il-
lumina Genome Analyzer II. Details of how the level of STAT3 binding and
histone modifications were calculated for all genes can be found in Table S1.615, May 28, 2010 ª2010 Elsevier Inc. 613
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3 days with anti-CD3, anti-CD28 alone, or with IL-6 (10 ng/ml) and TGF-
b (2.5 ng/ml). RNA was purified (MirVana miRNA isolation kit, Ambion), reverse
transcribed, and biotinylated (MessageAmp II-Biotin Enhanced Kit, Ambion).
Labeled aRNA (10 mg) was hybridized to GeneChip Mouse Genome 430 2.0
arrays (Affimetrix) in accordance with the manufacturer’s protocols. Expres-
sion was determined with GeneChip Operating Software (GCOS; v1.1.1) and
analysis was performed with GeneSpring software GX 10.0.1 (Agilent Technol-
ogies).
For quantitative PCR, RNA was purified as above and reverse transcribed
(Applied Biosystems). Taqman Master Mix and primers from Applied Biosys-
tems were used for qPCR reactions. Each assay was performed in triplicate
with an ABI Fast detection system and gene expression levels were normalized
to 18 s rRNA and internal controls (medium alone) with DDCt calculations.
Statistics
GraphPad Prism 4.0 was used for statistical analysis (unpaired, two-tailed,
t test with a confidence interval of 95%). Differences were considered statisti-
cally significant when p < 0.05.
ACCESSION NUMBERS
The ChIP-Seq and microarray data sets are available in the Gene Expression
Omnibus (GEO) database (http://www.ncbi.nlm.nih.gov/gds) under the acces-
sion numbers GSE21669, GSE21670, and GSE21671.
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